BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $3,000 | – | 800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 1,170,100 | $19,797,000 | 1.43% |
| ABNER HERRMAN & BROCK LLC | 240,500 | $4,069,000 | 0.69% |
| EAM Investors, LLC | 63,967 | $1,082,000 | 0.26% |
| CFO4Life Group, LLC | 12,003 | $203,000 | 0.07% |
| WINTON GROUP Ltd | 97,455 | $1,649,000 | 0.05% |
| Jump Financial, LLC | 11,000 | $186,000 | 0.04% |
| Merit Financial Group, LLC | 21,731 | $368,000 | 0.03% |
| SG3 Management, LLC | 50,000 | $846,000 | 0.03% |
| HAP Trading, LLC | 64,900 | $603,000 | 0.03% |
| SG3 Management, LLC | 47,200 | $799,000 | 0.03% |